ClinicalTrials.gg
Active, not recruitingNCT04245839TRANSCEND FLUpdated Nov 5, 2025

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

A Phase 2 interventional study of Fludarabine and Cyclophosphamide in Lymphoma, Non-Hodgkin, sponsored by Celgene. Active, not recruiting at 49 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-05.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
276
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies in Lymphoma, Non-Hodgkin by Bristol-Myers Squibb — 2 open to participants now, 5 under way, none of them phase 3. Lymphoma, Non-Hodgkin · Bristol-Myers Squibb.

Planned enrollment
7th of 46
276 · median 58
Started
2020
with 3 others
Phase 2
13 of 50
none open now
Registered
40th of 50
by date

Among the 50 studies in Lymphoma, Non-Hodgkin by Bristol-Myers Squibb, this one is the 7th largest by planned enrollment of the 46 interventional ones that give a count, is one of 4 that started in 2020, is one of 13 in phase 2, and was the 40th registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

2 of the 50 studies in Lymphoma, Non-Hodgkin by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Lymphoma, Non-Hodgkin by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL.

The study will be conducted in compliance with the International Council on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements.

This study is divided into three periods:

  • Pretreatment, which consists of screening assessments, leukapheresis and the Pretreatment evaluation;
  • Treatment, which starts with the administration of lymphodepleting (LD) chemotherapy and continues through JCAR017 administration at Day 1 with follow-up through Day 29;
  • Posttreatment, which includes follow-up assessments for disease status and safety for 5 years.
03

Conditions studied

  • Lymphoma, Non-Hodgkin

Keywords

  • B-cell Non-Hodgkin Lymphoma (NHL)
  • JCAR017
  • Relapsed or Refractory
  • Follicular Lymphoma
  • Marginal Zone Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. follicular lymphoma (FL) (Grade 1, 2 or 3a) or marginal zone lymphoma (MZL) confirmed within 6 months of screening, as assessed by local pathology
  2. Patients should have received at least one prior therapy that includes anti-CD20 and alkylating agent
  3. Follicular lymphoma patients: Received at least one . Patients that received one prior line of systemic therapy are eligible if they present with high risk features. Patients that received two or more prior lines of systemic therapy are eligible, assuming one of the prior lines includes anti-CD20 and alkylating agent (as listed in criterion 2)
  4. Marginal zone lymphoma patients: Received two or more prior lines of systemic therapy, assuming one of the prior lines includes anti-CD20 and alkylating agent (as listed in criterion 2) or relapsed after hematopoietic stem cell transplant
  5. (ECOG) performance status of 0 or 1
  6. Adequate organ function
  7. Adequate vascular access for leukapheresis procedure

Exclusion criteria

Exclusion Criteria:

  1. Evidence or history of composite Diffuse large B-cell lymphoma (DLBCL) and FL, or of transformed FL
  2. WHO subclassification of duodenal-type FL
  3. Central nervous system-only involvement by (subjects with secondary central nervous system (CNS) involvement are allowed on study)
  4. History of another primary malignancy that has not been in remission for at least 2 years, with the exception of non-invasive malignancies
  5. Prior CAR T-cell or other genetically-modified cell therapy
  6. History of or active (HIV)
  7. Active or active
  8. Uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate antibiotics or other treatment
  9. Active disease requiring therapy
  10. Presence of acute or chronic graft-versus-host=disease
  11. History of significant cardiovascular disease
  12. History or presence of central nervous system pathology
  13. Allogenic-hematopoietic stem cell transplant (Allo-) within 90 days of leukapheresis
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
276 participants (estimated)

Study arms

  • Experimental
    Administration of JCAR017

    * Subjects will be treated with fludarabine IV (30 mg/m2/day for 3 days) and cyclophosphamide IV (300 mg/m2/day for 3 days) prior to JCAR017 infusion. Refer to the most recent package inserts for further details on administration of these agents. * JCAR017 will be infused on Day 1 at a target dose of 100 × 10\^6 CAR-positive viable T cells (CAR+ T cells), 2 to 7 days after completion of LD chemotherapy. Each JCAR017 dose includes CD4+ CAR+ T cells and CD8+ CAR+ T cells.

    Drug: Fludarabine · Drug: Cyclophosphamide · Drug: JCAR017

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    Is defined as the percentage of participants achieving either a partial response (PR) or complete response (CR) at any time up to 60 months after JCAR017 treatment as assessed by PET-CT and/or CT using "The Lugano classification"

    Time frame: Up to 60 months

Secondary outcomes

  1. Complete response rate (CRR) as assessed but PET-CT and/or CT using "The Lugano Classification"

    Is defined as the percentage of subjects achieving a CR at any time up to 60 months after JCAR017 treatment

    Time frame: Up to 60 months

  2. Duration of Response (DOR) if Best Overall Response (BOR) is CR, as assessed by PET-CT and/or CT using "The Lugano Classification"

    is defined for subjects with a BOR of CR as the time from first response (CR or PR) to disease progression or death from any cause up to 60 months after JCAR017 treatment

    Time frame: Up to 60 months

  3. Duration of Response (DOR) as assessed by PET-CT and/or CT using "The Lugano Classification"

    is defined as the time from first response (CR or PR) to disease progression or death from any cause, whichever occurs first up to 60 months after JCAR017 treatment

    Time frame: Up to 60 months

  4. Progression-Free Survival (PFS) as assessed by PET-CT and/or CT using "The Lugano Classification"

    is defined as the time from start of JCAR017 to disease progression or death from any cause, whichever occurs first up to 60 months after JCAR017 treatment

    Time frame: Up to 60 months

  5. Overall Survival (OS)

    is defined as the time from start of JCAR017 to time of death due to any cause up to 60 months after JCAR017 treatment

    Time frame: Up to 60 months

  6. Adverse Events (AEs)

    An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE.

    Time frame: Up to 60 months

  7. Pharmacokinetics - Cmax

    Maximum concentration

    Time frame: Up to 60 months

  8. Pharmacokinetics - Tmax

    Time to maximum concentration

    Time frame: Up to 60 months

  9. Pharmacokinetics - AUC

    Area under the curve

    Time frame: Up to 60 months

  10. European Organization for Research and Treatment of Cancer - Quality of Life C30 questionnaire (EORTC QLQ-C30)

    is questionnaire that will be used as a measure of health-related quality of life. The EORTC QLQ-C30 is composed of both multi-item scales and single item measures. These include five functional scales (physical, role, emotional, cognitive and social), three symptom scales (fatigue, nausea/vomiting, and pain), a global health status/health-related quality of life (HRQoL) scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Each of the multi-item scales includes a different set of items - no item occurs in more than one scale.

    Time frame: Up to 24 months

  11. Functionality Assessment of Cancer Therapy Lymphoma Subscale (FACT-LymS)

    is a 15-item lymphoma-specific additional concerns subscale. This subscale addresses symptoms and functional limitations are important to lymphoma patients. The FACT-LymS items are scored on a 0 ("Not at all") to 4 ("Very much") response scale. Items are aggregated to a single score on a 0-60 scale. High scores indicate lower symptom burden.

    Time frame: Up to 24 months

07

Study locations

49 sites
  • Local Institution - 111
    Santa Monica, California 90095, United States
  • Local Institution - 107
    Aurora, Colorado 80045, United States
  • Local Institution - 105
    New Haven, Connecticut 06520, United States
  • Local Institution - 103
    Chicago, Illinois 60611, United States
  • Local Institution - 109
    Niles, Illinois 60714, United States
  • Local Institution - 122
    Iowa City, Iowa 52242, United States
  • Local Institution - 124
    Wichita, Kansas 67124, United States
  • Local Institution - 102
    Baltimore, Maryland 21201, United States
  • Local Institution - 100
    Boston, Massachusetts 02114, United States
  • Local Institution - 101
    Boston, Massachusetts 02215, United States
  • Local Institution - 127
    Detroit, Michigan 48201, United States
  • Local Institution - 123
    Morristown, New Jersey 07960, United States
  • Local Institution - 116
    New York, New York 10021, United States
  • Local Institution - 110
    Charlotte, North Carolina 28204, United States
  • Local Institution - 112
    Cleveland, Ohio 44195, United States
  • Local Institution - 114
    Portland, Oregon 97213, United States
  • Local Institution - 117
    Philadelphia, Pennsylvania 19104, United States
  • Local Institution - 113
    Sioux Falls, South Dakota 57105, United States
  • Local Institution - 121
    Dallas, Texas 75230-2510, United States
  • Local Institution - 104
    Houston, Texas 77030, United States
  • Local Institution - 119
    Houston, Texas 77030, United States
  • Local Institution - 115
    Charlottesville, Virginia 22903, United States
  • Local Institution - 108
    Seattle, Washington 98109, United States
  • Local Institution - 450
    Vienna, 1090, Austria
  • Local Institution - 150
    Toronto, Ontario M5G 2M9, Canada
  • Local Institution - 151
    Montreal, Quebec H1T 2M4, Canada
  • Local Institution - 252
    Lille, 59037, France
  • Local Institution - 251
    Montpellier, 34295, France
  • Local Institution - 255
    Paris, 75475, France
  • Local Institution - 250
    Pierre-Bénite, 69495, France
  • Local Institution - 253
    Rennes, 35023, France
  • Local Institution - 254
    Toulouse, 31100, France
  • Local Institution - 500
    Ulm, Baden-Wurttemberg 89081, Germany
  • Local Institution - 504
    Regensburg, Bavaria 93053, Germany
  • Local Institution - 501
    Cologne, 50937, Germany
  • Local Institution - 503
    Karlsruhe, 76135, Germany
  • Local Institution - 502
    Munich, 81377, Germany
  • Local Institution - 300
    Bergamo, 24127, Italy
  • Local Institution - 301
    Naples, 80131, Italy
  • Local Institution - 553
    Sapporo, Hokkaido 0608648, Japan
  • Local Institution - 550
    Chuo-ku, Tokyo 1040045, Japan
  • Local Institution - 551
    Minato-ku, Tokyo 105-8470, Japan
  • Local Institution - 552
    Fukuoka, 812-8582, Japan
  • Local Institution - 353
    Madrid, 28007, Spain
  • Local Institution - 350
    Salamanca, 37007, Spain
  • Local Institution - 351
    Seville, 41013, Spain
  • Local Institution - 600
    Stockholm, 14186, Sweden
  • Local Institution - 200
    London, NW1 2PG, United Kingdom
  • Local Institution - 201
    Manchester, M20 4BX, United Kingdom
08

References and documents

Publications

  • Ahmed S, Martin Garcia-Sancho A, Reguera-Ortega JL, Cartron G, Rapoport AP, Izutsu K, Ghesquieres H, Goto H, Palomba ML, Abramson JS, Borchmann P, Jaeger U, Kamdar M, Dreyling M, Subklewe M, Dahiya S, Nastoupil LJ, Bar M, Strocchia M, Raggi M, Moro Bueno L, Papuga J, Colicino S, Morschhauser F. Durable efficacy and manageable long-term safety of lisocabtagene maraleucel in 3L+ FL: 3-year update from TRANSCEND FL. Blood. 2026 Jul 1:blood.2026034327. doi: 10.1182/blood.2026034327. Online ahead of print. PubMed 42462111 ↗
  • Palomba ML, Schuster SJ, Karmali R, Skarbnik AP, Abramson JS, Ardeshna K, Borchmann P, Hill BT, Garcia-Sancho AM, Marcacci G, Rapoport AP, Cartron G, Fleury I, Izutsu K, Kamdar M, Mielke S, Barbui AM, Ortega JLR, Nastoupil LJ, Ahmed S, Bar M, Diaz L, Furustrand U, Diab V, Vedal M, Avilion A, Kumar J, Nishii R, Colicino S, Morschhauser F. Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study. Lancet. 2026 Mar 7;407(10532):963-975. doi: 10.1016/S0140-6736(25)02435-3. Epub 2026 Feb 12. PubMed 41692020 ↗
  • Morschhauser F, Dahiya S, Palomba ML, Martin Garcia-Sancho A, Reguera Ortega JL, Kuruvilla J, Jager U, Cartron G, Izutsu K, Dreyling M, Kahl B, Ghesquieres H, Ardeshna K, Goto H, Barbui AM, Abramson JS, Borchmann P, Fleury I, Mielke S, Skarbnik A, de Vos S, Kamdar M, Karmali R, Viardot A, Farazi T, Fasan O, Lymp J, Vedal M, Nishii R, Avilion A, Papuga J, Kumar J, Nastoupil LJ. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Nat Med. 2024 Aug;30(8):2199-2207. doi: 10.1038/s41591-024-02986-9. Epub 2024 Jun 3. PubMed 38830991 ↗

Individual participant data

Plan to share: Yes — Information relating to our policy on data sharing and the process for requesting data can be found at the following link: https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2020 (actual). Primary completion is estimated for Sep 2031, 134 months after the start.

Of 50 industry-sponsored phase 2 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 77. This study's planned 134 months is above that.

Counting every sponsor, half of 223 studies reached it within 65 months; a quarter within 41 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2020
First posted
Jan 29, 2020
StartActual
Jul 14, 2020
Primary completionEst.
Sep 30, 2031
CompletionEst.
Sep 30, 2031
Last update
Nov 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04245839
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Jan 29, 2020
Start date
Jul 14, 2020
Primary completion
Sep 30, 2031 (estimated)
Completion
Sep 30, 2031 (estimated)
Last update
Nov 5, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisocabtagene maraleucel

Start the discussion